Abstracts tagged "Dermatology"

Abstract Number: 1166 • ACR Convergence 2025
Biomarkers Associated with Left Atrial Structure and Function in Individuals with Psoriasis
Julie Borchsenius¹, Maria Dons², Morten Sengeløv³, Flemming Olsen⁴, Caroline Espersen⁴, Kristoffer Skaarup³, Mats Lassen⁴, Niklas Johansen⁴, Filip Davidovski³, Manan Pareek⁴, Brittany Weber⁵, Claus Zachariae⁶, Lone Skov⁶ and Tor Biering-Sørensen³, ¹CTCPR / Center for translational cardiology and pragmatic research trials, Charlottenlund, Denmark, ²Copenhagen University Hospital Gentofte, Copenhagen, Hovedstaden, Denmark, ³Center for Translational Cardiology and Pragmatic Randomized Trials, Dep. of Cardiology, Copenhagen University Hospital - Gentofte, Copenhagen, Hovedstaden, Denmark, ⁴CTCPR / Center for translational cardiology and pragmatic research trials, Copenhagen, Denmark, ⁵Brigham and Women's Hospital, DEDHAM, MA, ⁶Dep. of Dermatology and Allergy, Copenhagen University Hospital – Herlev & Gentofte, Copenhagen, Hovedstaden, Denmark
Background/Purpose: Individuals with psoriasis are at increased risk of developing heart disease. Echocardiographic parameters of impaired left atrial (LA) strain (Peak atrial contraction and longitudinal…
Abstract Number: 1152 • ACR Convergence 2025
Cutaneous Panniculitis in Rheumatology: A Descriptive Cohort Study from a Multidisciplinary Experience
Claudia Campos-Fabre¹, Carlota Ureta-Moneva¹, Elena Sendagorta¹, Jose Rodríguez-Gago¹, Maria José Beato¹, Agustin Remesal², Rosa Alcobendas¹, Clara Udaondo¹, Gema Bonilla³, Laura Nuño⁴, Irene Monjo Henry², Carolina Tornero⁵ and Chamaida Plasencia-Rodríguez², ¹La Paz University Hospital, Madrid, Spain, ²Hospital Universitario La Paz, Madrid, Spain, ³Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ⁴Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁵Hospital La Paz, Madrid, Spain
Background/Purpose: Panniculitis refers to inflammatory disorders of subcutaneous fat that pose diagnostic challenges due to nonspecific clinical features and overlapping histopathological patterns. Although it can…
Abstract Number: 0998 • ACR Convergence 2025
Preclinical Characterization of a Novel Bi-specific Antibody Targeting IL-23p19 and IL-36R for The Treatment of Autoimmune Diseases
qianqian yin¹, changqing run¹, kaili liu¹, xueqin cui¹, fanpeng Meng¹, yanru fan¹, yifei yang¹, wei ye¹, Lu Su², yuan lin¹ and cheng liao¹, ¹Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China (People's Republic), ²Jiangsu Hengrui Pharmaceuticals, Shanghai, Shanghai, China
Background/Purpose: IL-23 is a pivotal cytokine driving IL-17-mediated inflammation, and its inhibition has shown efficacy in Th17-associated autoimmune diseases. However, patient heterogeneity and compensatory pathways…
Abstract Number: 2699 • ACR Convergence 2025
Cutaneous IgA Vasculitis: Emulation of a Target Trial from a European Multicentric Retrospective Study
Elena Biancamaria Mariotti¹, Boris Sorin², William Lutz³, Chloé Grolleau³, Thomas Bettuzzi⁴, Caterina Ricordi⁵, Santos Castañeda⁶, Luisa Herda⁷, Cord Sunderkotter⁷, Rodérau Outh⁸, Romain Paule⁹, Alexandra Audemard-Verger¹⁰, Marzia Caproni¹¹, Angelo Valerio Marzano¹², Pietro Quaglino¹³, Laura Atzori¹⁴, Julien Campagne¹⁵, Mehemt Erkan¹⁶, Nabil Belfeki¹⁷, Marijan Frkovic¹⁸, Nicolas Dupin¹⁹, Raphael Porcher²⁰, Marie Jachiet²¹ and Benjamin Terrier¹⁹, ¹University of Florence, Azienda USL Toscana Centro, Department of Dermatology, Florence, Firenze, Italy, ²Assistance Publique Hôpitaux de Paris, Paris, France, ³University Paris Cité, Hospital Saint Louis, Dermatology department, Paris, Paris, France, ⁴Université Paris Est Créteil Val de Marne, Hôpital Henri-Mondor (APHP), Service de dermatologie, EpiDermE, Paris, France, ⁵AUSL-IRCCS Reggio Emilia, Parma, Italy, ⁶Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁷Department of Dermatology and Venereology, Martin Luther University Halle-Wittenberg, Halle (Saale), Halle, Germany, ⁸Department of Internal Medicine, Centre Hospitalier de Perpignan, Perpignan, France., Clermont-Ferrand, France, ⁹Hospital Foch, Service de medicine interne, Suresnes, Paris, Suresnes, France, ¹⁰Department of Internal Medicine, Tours University Hospital, Tours, France., Tours, France, ¹¹University of Florence, Azienda USL Toscana Centro, Department of Dermatology, Florence, Florence, Italy, ¹²Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Milan, Italy, ¹³University of Turin, Department of Medical Sciences, Section of Dermatology, Turin, Torino, Italy, ¹⁴Dermatology Clinic, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Cagliari, Italy, ¹⁵Hospital Robert Schuman, Metz, France, ¹⁶Hacettepe University Faculty of Medicine Department of Pediatric Rheumatology Ankara, Türkiye, Ankara, Turkey, ¹⁷Head of the Internal Medicine and Clinical Immunology Department South Île de France Health Hospital Group, Melun Center, Melun, France, ¹⁸Division for clinical immunology and rheumatology, Department of pediatrics UHC Zagreb / School of Medicine Zagreb Croatia, Zagabria, Croatia, ¹⁹Cochin Hospital, Paris, France, ²⁰Université Paris Cité and Université Sorbonne Paris Nord, INSERM, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), Paris, France, Paris, France, ²¹University Paris Cité, Hôpital Saint-Louis, Dermatology department, Paris, Paris, France
Background/Purpose: Immunoglobulin A vasculitis (IgAV) is a small vessel vasculitis marked by IgA, deposition, palpable purpura with lower body predilection and variable joints, kidney and…
Abstract Number: 0926 • ACR Convergence 2025
Discovery and Characterization of SIM0711: a Potent and Selective IRAK4 PROTAC with Improved Efficacy and Safety
Minyun Zhou¹, Peng Gu², Mengyu Wang³, Yuxi Yan², Li Sun³, Yiling Chen³, Xin Wang³, Feng Tang¹, Shunwei Zhu² and Xiaofeng Zhao⁴, ¹State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical group, Nanjing, ²State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Shanghai, China (People's Republic), ³State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic), ⁴State Key Laboratory of Neurology and oncolog Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic)
Background/Purpose: IRAK4 plays a pivotal role in the innate immune response by acting downstream of Toll-like receptors (TLRs) and the interleukin-1 receptor (IL-1R), with both…
Abstract Number: 2608 • ACR Convergence 2025
Metabolic dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factors, and Cardiac Manifestations in Psoriasis
Maria Dons¹, Charlotte Näslund-Koch², Morten Sengeløv³, Sofie Bøgh-Sørensen³, Kristoffer Skaarup³, Marianne Bengtson Løvendorf⁴, Filip Davidovski³, Anne Marie Reimer Jensen³, Brittany Weber⁵, Lise Lotte Gluud⁶, Claus Zachariae², Lone Skov² and Tor Biering-Sørensen³, ¹Copenhagen University Hospital Gentofte, Copenhagen, Hovedstaden, Denmark, ²Dep. of Dermatology and Allergy, Copenhagen University Hospital – Herlev & Gentofte, Copenhagen, Hovedstaden, Denmark, ³Center for Translational Cardiology and Pragmatic Randomized Trials, Dep. of Cardiology, Copenhagen University Hospital - Gentofte, Copenhagen, Hovedstaden, Denmark, ⁴Department of Dermatology and Allergy, Copenhagen University Hospital – Herlev & Gentofte, Copenhagen, Hovedstaden, Denmark, ⁵Brigham and Women's Hospital, DEDHAM, MA, ⁶Gastro Unit, Copenhagen University Hospital – Hvidovre, Copenhagen, Hovedstaden, Denmark
Background/Purpose: Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a cardiometabolic risk factor. Individuals with psoriasis have a high prevalence of MASLD, yet…
Abstract Number: 0648 • ACR Convergence 2025
Real World Comparative Use of Anifrolumab in Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus: A Multicenter Cohort Study
Rajaie Namas¹, Sarah Al Qassimi², Rowaida Abdou³, Jawahir Alameri², Reem Alblooshi⁴, Fatima Abdulla⁴, Muriel Ghosn⁴, Amir Malik⁴, Raghda Almaashari⁴, Fulvio Salvo⁴, Mohamed Abuzakouk⁴, Atheer Al Ansari⁵, Hazem Helmy Ali Rifaai⁵, Ahlam Almarzooqi⁶, Asia Mubashir⁷, Ahmed Aldhaheri⁴, Suzan Attar⁸ and Mohamed Elarabi⁹, ¹Cleveland Clinic Abu Dhabi, Detroit, MI, ²Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, ³NMC Specialty Hospital Abu Dhabi, Abu Dhabi, United Arab Emirates, ⁴Cleveland Clinic Abu Dhabi, Abu Dhabi, ⁵Mediclinic, Abu Dhabi, United Arab Emirates, ⁶Emirates Health Services, Sharjah, United Arab Emirates, ⁷Cleveland Clinic, Abu Dhabi, Abu Dhabi, United Arab Emirates, ⁸King Abdulaziz University, Saudi Arabia, Jeddah, Saudi Arabia, ⁹Cleveland Clinic Abu Dhabi, Hannon, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiorgan organ damage, and early mortality. Anifrolumab (ANI), a human monoclonal antibody targeting the…
Abstract Number: 2428 • ACR Convergence 2025
Differences in Dyspigmentation and Scarring Across Cutaneous Lupus Erythematosus Categories and Subtypes
Shae Chambers¹, Aretha On², Xiwei Yang², Lais Lopes Almeida Gomes¹, Touraj Khosravi-Hafshejani³, Hammad Ali³, Rui Feng⁴ and Victoria Werth¹, ¹University of Pennsylvania, Philadelphia, PA, ²Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, U.S./Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, U.S., Philadelphia, PA, ⁴Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, Philadelphia, PA
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a chronic autoimmune disease marked by skin lesions that can vary in appearance and severity. Subacute cutaneous erythematosus (SCLE),…
Abstract Number: 0574 • ACR Convergence 2025
Bimekizumab 3-Year Efficacy In Patients With Psoriasis And Risk Factors For Progression To Psoriatic Arthritis Or Screening Positive For Psoriatic Arthritis: Long-Term Results From Five Phase 3/3b Trials
Richard G. Langley¹, Joseph F Merola², Diamant Thaçi³, Emi Nishida⁴, Bruce Strober⁵, Richard B. Warren⁶, José M. López Pinto⁷, Christina Crater⁸, Sarah Kavanagh⁸ and Paolo Gisondi⁹, ¹Dalhousie University, Halifax, NS, Canada, ²Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ³Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁴Nagoya City West Medical Center, Nagoya, Japan, ⁵Department of Dermatology, Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell, CT, ⁶Dermatology Centre, Northern Care Alliance, NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ⁷UCB, Madrid, Spain, ⁸UCB, Morrisville, NC, ⁹Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy
Background/Purpose: Psoriatic arthritis (PsA) affects up to one-third of patients with psoriasis;1 early identification and intervention for patients with psoriasis and risk factors (RFs) for…
Abstract Number: 2409 • ACR Convergence 2025
Cutaneous Lupus Activity Investigator’s Global Assessment―Revised (CLA-IGA-R) Content Validity: Cutaneous Lupus Erythematosus (CLE) Patient Qualitative Study
Joseph F Merola¹, Weihong Yang², Qianyun Li², Helen Doll³, Jason Randall³, Catherine Barbey⁴ and Feng Zeng², ¹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ²Biogen, Cambridge, MA, ³Clinical Outcomes Solutions, Folkestone, Kent, United Kingdom, ⁴Biogen, Baar, Switzerland
Background/Purpose: The Cutaneous Lupus Activity Investigator’s Global Assessment-Revised (CLA-IGA-R) is an emerging clinician-reported outcome measure for severity of Cutaneous Lupus Erythematosus (CLE) disease activity, developed…
Abstract Number: 0562 • ACR Convergence 2025
Icotrokinra (ICO), a Novel Targeted Oral Peptide, in Patients (Pts) With Psoriatic Disease: Exploratory Assessments From a Phase 2 Psoriasis (PsO) Study Informing a Phase 3 Clinical Program in Psoriatic Arthritis (PsA)
Joseph F Merola¹, Philip J. Mease², Laura Coates³, Iain McInnes⁴, Peter Nash⁵, Alexis Ogdie⁶, Lihi Eder⁷, mitsumasa kishimoto⁸, Anna Beutler⁹, Konstantina Psachoulia⁹, Shihong Sheng¹⁰, Bei Zhou¹¹, Mehrdad Javidi¹², Chandni Valiathan¹², Charles Iaconangelo¹⁰, Ya-Wen Yang¹³, Arun Kannan¹³, Chetan S. Karyekar⁹ and Tasneam Shagroni⁹, ¹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁴University of Glasgow, Glasgow, United Kingdom, ⁵Griffith University and U of Queensland, Maroochydore, Queensland, Australia, Queensland, Australia, ⁶University of Pennsylvania, Philadelphia, PA, ⁷University of Toronto, Toronto, ON, Canada, ⁸Kyorin University School of Medicine, Tokyo, Japan, ⁹Johnson & Johnson, Spring House, PA, USA, Spring House, ¹⁰Johnson & Johnson, Chesterbrook, PA, USA, Chesterbrook, ¹¹Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ¹²Johnson & Johnson, San Diego, CA, USA, San Diego, ¹³Johnson & Johnson, San Diego, CA, USA, San Diego, CA
Background/Purpose: PsA affects ~20-30% of pts with PsO, causing articular inflammation/damage, and impaired health-related quality of life (HRQoL). ICO, a novel targeted oral peptide that…
Abstract Number: 2374 • ACR Convergence 2025
Bimekizumab Efficacy And Safety Through 5 Years In Patients With Moderate To Severe Plaque Psoriasis In The US And Canada
Andrew Blauvelt¹, Saakshi Khattri², Phoebe Rich³, Ronald Vender⁴, Kenneth B. Gordon⁵, Balint Szilagyi⁶, Heather Herr⁷, Bertram Knapp⁶, Delphine Deherder⁸, Sarah Kavanagh⁹ and Kim Papp¹⁰, ¹Blauvelt Consulting, LLC, Portland, OR, ²The Mount Sinai Hospital, New York, NY, ³Oregon Dermatology and Research Center, Portland, OR, ⁴Dermatrials Research Inc., Hamilton, ON, Canada, ⁵Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI, ⁶UCB, Monheim am Rhein, Germany, ⁷UCB, Smyrna, GA, ⁸UCB, Braine-l'Alleud, Belgium, ⁹UCB, Morrisville, NC, ¹⁰Probity Medical Research and Alliance Clinical Trials, Waterloo, and Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Given the chronic nature of psoriasis, and the loss of response observed with biologic therapies over time, it is crucial to establish the long-term…
Abstract Number: 0551 • ACR Convergence 2025
Enthesitis Beyond the Surface: Ultrasonographic Unmasking of Preclinical Psoriatic Arthritis in Cutaneous Psoriasis
Victor Cazac¹ and Eugeniu Russu², ¹Norwalk Hospital, Nuvance Health, Connecticut, ²"Nicolae Testemitanu" State Medical and Pharmaceutical University; ”Timofei Moșneaga” Republican Clinical Hospital, Chisinau, Moldova
Background/Purpose: Psoriatic arthritis (PsA) develops insidiously from psoriasis (PsO), with enthesitis representing a critical initial site of inflammation. Musculoskeletal ultrasonography (MSUS) enables the identification of…
Abstract Number: 1134 • ACR Convergence 2024
First-in-Human Evaluation of the Safety, Tolerability and Pharmacokinetics of the T Cell Receptor Signal Modulator AX-158
Christopher VanDeusen¹, Andres Gagete¹, Annelize Koch² and D Scott Batty Jr¹, ¹Artax Biopharma, Inc, Cambridge, MA, ²Simbec-Orion, Merthyr Tydfil, Wales, United Kingdom
Background/Purpose: Nck is a cytosolic protein that binds a domain of the T cell receptor (TCR) following TCR interaction to amplify responses from low affinity…
Abstract Number: 1537 • ACR Convergence 2024
Discovery of VENT-03: A Novel Clinical cGAS Inhibitor for the Treatment of SLE and Other Autoimmune Diseases
Kelly A. Pike¹, Nadine Fradet¹, Samuel Gaudreault¹, Alexander M Skeldon², Ramsay E. Beveridge², Patrick Cyr², Nicolas Sgarioto², Philippe Le Gros³, Eleftheria Seliniotakis², Valerie Dumais², Jacklyn Smith², James I.P Stewart², Mehrnaz Gharaee-Kermani⁴, Michelle J Kahlenberg⁴ and Michael A. Crackower², ¹Ventus Therapeutics, Saint-Laurent, QC, Canada, ²Ventus Therapeutics, Saint-Laurent, Canada, ³Ventus Therapeutics, Montreal, QC, Canada, ⁴University of Michigan, Ann Arbor, MI
Background/Purpose: Cyclic GMP-AMP synthase (cGAS) is a nucleic acid sensor that plays a central role in anti-viral responses. Following the detection of intracellular double-stranded DNA,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].